Jefferies Pounds the Table on BioXcel Therapeutics (BTAI), Data Selloff is a Buying Opportunity, PT Raised $94
Tweet Send to a Friend
Jefferies analyst Chris Howerton raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $94.00 (from $82.00) after shares sold ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
